These studies have highlighted that a large battery of angiogenesis-associated gene products are expressed in a HIF-dependent manner in diabetic eye diseases and that, whereas current therapies target only one of them (VEGFA), HIF inhibitors have a much broader effect on gene expression, which may translate into a higher response rate among patients with diabetic eye diseases, less than half of whom respond well to anti-VEGFA therapies (15). The gene discussed is VEGFA; the disease is diabetic eye disease.